After Hours
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Yahoo Finance discussed the stock recently as it posted Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. The current market capitalization of Kura Oncology Inc is $1.74B. A total of 1.2 million shares were traded on the day, compared to an average of 1.61M shares.
In the most recent transaction, DALE STEPHEN sold 4,825 shares of KURA for 21.55 per share on Jan 30 ’24. After the transaction, the Chief Medical Officer now owns 38,817 company shares. In a previous transaction on Jan 29 ’24, DALE STEPHEN sold 7,158 shares at 17.80 per share. KURA shares that Chief Medical Officer owns now total 43,642.
Among the insiders who sold shares, DOYLE THOMAS JAMES disposed of 2,318 shares on Jan 29 ’24 at a per-share price of $17.80. This resulted in the SVP, Finance & Accounting holding 48,093 shares of KURA after the transaction. In another insider transaction, Bair Teresa Brophy sold 2,053 shares at $17.80 per share on Jan 29 ’24. Company shares held by the Chief Legal Officer now total 68,979.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. In terms of 52-week highs and lows, KURA has a high of $23.75 and a low of $7.41.
As of this writing, KURA has an earnings estimate of -$0.55 per share for the current quarter. EPS was calculated based on a consensus of 11 estimates, with a high estimate of -$0.44 per share and a lower estimate of -$0.68. The company reported an EPS of -$0.5 in the last quarter, which was 9.10% higher than expectations of -$0.55.
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. KURA’s latest balance sheet shows that the firm has $517.96M in Cash & Short Term Investments as of fiscal 2021. There were $6.88M in debt and $22.45M in liabilities at the time. Its Book Value Per Share was $5.34, while its Total Shareholder’s Equity was $506.61M.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for KURA is Buy with a score of 4.86.
